{"id":"ly2062430","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE10A is an enzyme highly expressed in the striatum and other brain regions involved in motor control and cognition. By inhibiting PDE10A, the drug increases levels of cyclic nucleotides (cAMP and cGMP), which modulate neuronal activity and may restore balance in dysregulated neural circuits. This mechanism has been explored for neuropsychiatric and neurodegenerative disorders.","oneSentence":"LY2062430 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:53.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Huntington's disease"}]},"trialDetails":[{"nctId":"NCT01760005","phase":"PHASE2, PHASE3","title":"Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2012-12","conditions":"Alzheimers Disease, Dementia, Alzheimers Disease, Familial","enrollment":490},{"nctId":"NCT02008357","phase":"PHASE3","title":"Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-02-28","conditions":"Cognition Disorders","enrollment":1169},{"nctId":"NCT04623242","phase":"PHASE2, PHASE3","title":"Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2012-12","conditions":"Alzheimers Disease, Dementia, Alzheimers Disease, Familial","enrollment":194},{"nctId":"NCT02614131","phase":"PHASE1","title":"A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2015-12","conditions":"Healthy, Alzheimer's Disease, Mild Cognitive Impairment","enrollment":50},{"nctId":"NCT02760602","phase":"PHASE3","title":"A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2016-06","conditions":"Alzheimer's Disease","enrollment":26},{"nctId":"NCT01900665","phase":"PHASE3","title":"Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2013-07","conditions":"Alzheimer's Disease","enrollment":2129},{"nctId":"NCT01127633","phase":"PHASE3","title":"Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Alzheimer's Disease","enrollment":1457},{"nctId":"NCT00904683","phase":"PHASE3","title":"Effect of LY2062430 on the Progression of Alzheimer's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-05","conditions":"Alzheimer's Disease","enrollment":1040},{"nctId":"NCT00905372","phase":"PHASE3","title":"Effect of LY2062430 on the Progression of Alzheimer's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-05","conditions":"Alzheimer's Disease","enrollment":1000},{"nctId":"NCT01148498","phase":"PHASE2","title":"A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-08","conditions":"Alzheimer's Disease","enrollment":55},{"nctId":"NCT00749216","phase":"PHASE2","title":"Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-09","conditions":"Alzheimer's Disease","enrollment":33},{"nctId":"NCT00329082","phase":"PHASE2","title":"Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-05","conditions":"Alzheimer's Disease","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["A Beta Antibody","Solanezumab (*USAN adopted name, INN pending)"],"phase":"phase_3","status":"active","brandName":"LY2062430","genericName":"LY2062430","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY2062430 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain. Used for Huntington's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}